Last reviewed · How we verify
Flublok™ Quadrivalent by Sanofi, Inc.
Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates the immune system to produce antibodies against four strains of influenza virus.
Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults 18 years of age and older.
At a glance
| Generic name | Flublok™ Quadrivalent by Sanofi, Inc. |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Recombinant inactivated influenza vaccine |
| Target | Influenza hemagglutinin (HA) protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant hemagglutinin proteins from four influenza virus strains (two A strains and two B strains) manufactured in insect cells using baculovirus expression technology. These proteins are recognized by the immune system as foreign antigens, triggering both humoral and cellular immune responses that generate protective antibodies and memory immunity against the targeted influenza strains.
Approved indications
- Seasonal influenza prevention in adults 18 years of age and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Headache
- Myalgia
- Fatigue
Key clinical trials
- Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP (PHASE4)
- Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: